Title :

Denutrition status prevails over a standard AML risk assessment in older adults

Author(s) :

Simon, Laura [Auteur]
Guy's and St Thomas' NHS Foundation Trust
Caulier, Alexis [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie
Berthon, Céline [Auteur]
Service des Maladies du Sang [CHU Lille] [SMS]
Hôpital Claude Huriez [Lille]
Boyer, Thomas [Auteur]
CHU Amiens-Picardie
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
Harrivel, Véronique [Auteur]
CHU Amiens-Picardie
Joris, Magalie [Auteur]
CHU Amiens-Picardie
Leduc, Isabelle [Auteur]
Centre Hospitalier d'Abbeville
Duployez, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service d'Hématologie Cellulaire [Lille]
Preudhomme, Claude [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Marolleau, Jean-Pierre [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
Laboratoire d'Hématologie [CHU Amiens]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie

Journal title :

Current Research in Translational Medicine

Pages :

103500

Publisher :

Elsevier-Masson SAS

Publication date :

2025-02

ISSN :

2452-3186

English keyword(s) :

Acute myeloid leukemia
frail
unfit
non-intensive chemotherapy

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hématologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Gériatrie et gérontologie

English abstract : [en]

Older adults with acute myeloid leukemia (AML) have a poor prognosis because frailty and the characteristics of the disease limit the use of intensive chemotherapy (ICT). Treatment with 5-azacitidine (5-AZA) or low-dose ...
Show more >Older adults with acute myeloid leukemia (AML) have a poor prognosis because frailty and the characteristics of the disease limit the use of intensive chemotherapy (ICT). Treatment with 5-azacitidine (5-AZA) or low-dose cytarabine (LDAC) – with or without venetoclax – is currently recommended in this setting. However, we lack real-life data on response rates and treatment outcomes.We conducted a retrospective, multicenter registry study of 279 older adults with AML (median [interquartile range (IQR)] age: 76 [70–81]) having undergone first-line treatment with LDAC (n=87) or 5-AZA (n=192) between 2009 and 2019 (i.e. mainly before the venetoclax era) in a university medical center in France. The complete remission rate was 27.3% overall. After a median follow-up period of 6.9 months, the median [IQR] overall survival (OS) time was shorter in the LDAC group (4.8 months [2.13–14.41]) than in the 5-AZA group (8.9 months [3.2–13.5]; p=0.046). Ultimately, however, the OS rates were similar in the LDAC and 5-AZA groups (hazard ratio [HR]: 95% confidence interval [CI]: 1.37 [0.92-2.04], p= 0.12).None of the conventional markers with prognostic value in younger patients receiving ICT (such as those in the European LeukemiaNet classification) appeared to predict the outcome in our population of older patients. Albumin <30 g/L was the only factor that predicted day-30 mortality and OS (adjusted odds ratio [95%CI]: 6.25 [2.08 – 20.0]; p<0.001; adjusted HR [95%CI]: 0.65 [0.44-0.96]; p=0.030).Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL

Submission date :

2025-02-08T04:36:22Z